Medicilon(SH:688202) Hua Xia Shi Bao·2025-09-29 03:51Core Viewpoint - The legal dispute between Medisi (688202.SH) and its former client Hongxu Biotech involves a significant compensation claim of approximately 159 million yuan, which is about 30 times the service contract amount, raising concerns in the capital market [2][3][4]. Group 1: Background of the Dispute - The dispute traces back to December 18, 2020, when Medisi signed a technical service contract with Hongxu Biotech to conduct non-clinical safety evaluations for a biopharmaceutical project [3][4]. - The project, named "HX-100101-1 injection," aims to treat type 2 diabetes and is part of a highly competitive market with major players like Eli Lilly and domestic companies such as Hengrui Medicine and Innovent Biologics [3][4]. Group 2: Claims and Counterclaims - Hongxu Biotech claims that Medisi failed to deliver the required safety evaluation reports on time, leading to delays in obtaining clinical trial approvals from both the National Medical Products Administration (NMPA) and the FDA [4][5]. - Medisi asserts that it fulfilled its contractual obligations and that the delays were primarily due to Hongxu Biotech's late delivery of samples and other external factors, including the COVID-19 pandemic [5][6]. Group 3: Legal Proceedings and Market Reactions - The lawsuit was filed in July 2023, and the court has frozen Medisi's bank accounts as part of the asset preservation measures [4][5]. - The case has attracted significant attention in the market, as it raises questions about the collaboration models and contractual obligations within the Chinese innovative drug development industry [8].